Financial Performance - The total revenue for the fiscal year ended December 31, 2023, was HKD 45,230,000, a decrease of 16.5% compared to HKD 54,216,000 in 2022[5] - Gross profit for the same period was HKD 27,945,000, down 19.7% from HKD 34,825,000 in the previous year[5] - The net loss for the year was HKD 26,957,000, an improvement of 33.1% compared to a net loss of HKD 40,349,000 in 2022[5] - Basic and diluted loss per share was HKD 3.88, compared to HKD 7.28 in the prior year, indicating a reduction in loss per share by 46.5%[5] - The total comprehensive income for the group was impacted by a net loss of HKD (3,904) thousand in 2023, compared to a loss of HKD (5,030) thousand in 2022, showing an improvement[22] - The net loss before tax for 2023 was HKD 15,484,000, an improvement from a loss of HKD 29,036,000 in 2022[32] - The company recorded a net loss of approximately HKD 27 million for the fiscal year 2023, a decrease from a net loss of approximately HKD 40.3 million in the previous year, primarily due to an increase in fair value gains of HKD 8.6 million and a reduction in administrative expenses of HKD 15.9 million[45] Assets and Liabilities - Total assets decreased to HKD 256,769,000 from HKD 289,312,000, reflecting a decline of 11.2% year-over-year[9] - Non-current assets decreased to HKD 121,700,000 from HKD 143,718,000, a reduction of 15.3%[9] - Cash and cash equivalents at year-end were HKD 20,879,000, down from HKD 26,496,000, a decrease of 21.5%[9] - Accounts receivable decreased to HKD 6,387,000 in 2023 from HKD 15,992,000 in 2022, a reduction of 60%[35] - The total amount of loans provided to third parties was HKD 200,760,000, slightly down from HKD 200,850,000 in 2022[38] - The expected credit loss provision for loans was HKD 69,536,000 in 2023, compared to HKD 66,575,000 in 2022, indicating a slight increase[38] - The company’s total liabilities include accounts payable of HKD 4.3 million and other payables of HKD 37.4 million as of the reporting date[44] Segment Performance - The healthcare segment generated revenue of HKD 27,366 thousand in 2023, down from HKD 37,702 thousand in 2022, representing a decline of approximately 27.5%[22] - The lending and related businesses segment reported an increase in interest income from HKD 16,514 thousand in 2022 to HKD 17,864 thousand in 2023, an increase of about 8.2%[22] - The investment holding segment reported a loss before tax of HKD (13,243) thousand in 2023, compared to a profit of HKD 18,242 thousand in 2022, indicating a significant decline in performance[22] - The total reported segment revenue for 2023 was HKD 45,382 thousand, down from HKD 54,244 thousand in 2022, a decrease of approximately 16.3%[22] - Medical-related services revenue decreased to HKD 27,366,000 in 2023 from HKD 37,702,000 in 2022, representing a decline of 27.5%[24] - The medical segment generated revenue of approximately HKD 25.6 million in fiscal year 2023, down from HKD 31.1 million in the previous year, with a net loss of approximately HKD 17.9 million compared to HKD 19 million in the prior year[47] Administrative and Other Expenses - Administrative expenses were reduced to HKD 40,752,000 from HKD 56,633,000, a decrease of 28.1%[5] - The company incurred administrative expenses of HKD 20,039,000 in 2023, down from HKD 26,961,000 in 2022, a decrease of 25.5%[31] - The interest expense on lease liabilities was HKD 3,543,000 in 2023, a decrease from HKD 3,959,000 in 2022, reflecting a reduction of 10.5%[28] Dividends and Future Plans - The company did not declare any final or interim dividends for the year ending December 31, 2023, consistent with 2022[33] - The company has not recommended the distribution of a final dividend for the fiscal year 2023[49] - The company plans to continue expanding its medical and cosmetic surgery services in China and other Asian markets, anticipating growth in consumer spending in the medical beauty industry[50] - The group will continue to hold various securities and will monitor and adjust the investment portfolio as needed to adapt to the economic environment[52] - The group is actively seeking other business opportunities to diversify and increase revenue sources[54] Credit and Risk Management - The company recognized expected credit loss of HKD 10,013,000, significantly higher than HKD 800,000 in the previous year[5] - The company will adopt more cautious credit assessments and procedures in its lending and related businesses due to the adverse impacts of trade disputes and the COVID-19 pandemic[51] Bankruptcy Proceedings - The company has initiated bankruptcy proceedings against the first guarantor, with a claim amount of approximately USD 12 million submitted on May 19, 2022[41] Segment Reporting - The group confirmed deferred tax assets related to temporary differences, which are expected to offset taxable profits in the future, with no significant impact on financial performance[17] - The group has identified four reportable segments: Investment Holding, Healthcare, Lending and Related Businesses, and Hotels, with no combined operating segments[18]
天元医疗(00557) - 2023 - 年度业绩